← Evidence library

BIB_380

AMBLor (AMBRA1 + loricrin IHC) — validated prognostic biomarker for non-ulcerated AJCC Stage I/II cutaneous melanoma: Lovat 2024 BJD n=840 multi-cohort validation (NPV 96.5–97.6%; RFS 97.6% low-risk vs 78.3% at-risk); UKCA-marked UK IVD September 2024; NICE MIB294 (May 2022) supports use for prognostic stratification and SLNB decision-making; commercially available at £175–195 via Newcastle Hospitals UKAS send-away service (~5 days). DIRECTLY APPLICABLE to this patient at Stage IB (0.8mm) if final WLE histology confirms non-ulcerated status (which is currently an open unknown). BRIEF RECOMMEND…

Evidence grade

B

Tier

2 (Lovat 2024 British Journal of Dermatolo

Cited by tasks

15, 24

Identifiers

PMC6973157 · DOI:10.1093/bjd/ljad459

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_380/findings.md (research corpus). This page is a short context summary — not individualised medical advice.